Barclays Maintains Overweight on Reata Pharmaceuticals, Raises Price Target to $98

Benzinga · 05/11/2023 05:16
Barclays analyst Carter Gould maintains Reata Pharmaceuticals (NASDAQ:RETA) with a Overweight and raises the price target from $90 to $98.